BioSpace News Archive

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients with advanced or metastatic solid tumors that have progressed during or after standard of care therapy

Catalent, Inc. announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent’s commercial gene therapy manufacturing facility located in Harmans, Maryland.

Virpax today announced the signing of a technology license agreement with Nanomerics Ltd. (“Nanomerics”) for the exclusive North America rights to use Nanomerics’ High-Density Molecular Masking Spray

Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX ® (cabozantinib) in Combination With Opdivo ® (nivolumab) for Advanced Renal Cell Carcinoma – Submission based on the phase 3 pivotal CheckMate -9ER trial, which met its primary endpoint of significantly improving progression-free survival and secondary endpoints of overall survival and objective response rate – ALAMEDA, Calif.--( B

Nascent Biotech, Inc (OTCQB:NBIO) announced today that it is closing on a direct private placement with aggregate proceeds of $740,000. The proceeds allow the Company to complete the required testing for removing the partial clinical trial hold, imposed by the FDA, and will permit the company to begin the Phase I clinical trials on brain cancer.

Accelerates Plans to Enhance its Board Composition by Committing to Add a New Independent Director Following a Professionally-Managed Search Process that Includes Stockholder Input Augments Existing Cost Reduction Efforts by Capping Management Compensation and Director Fees at Their Current Levels For the Next Two Years Reaches Agreement with Stockholder, Resulting in a Withdrawal of his Nomination Notice and Certain Other Demands Relating t

Aug. 24, 2020 12:08 UTC Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin ® (Bevacizumab) Biosimilar BAT1706 in China GUANGZHOU & BEIJING & CAMBRIDGE, Mass--( BUSINESS WIRE )-- Bio-Thera Solutions, Ltd., a commercial stage biopharmaceutical company (688177.SH) and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), today announced that the companies have executed a license, distribution, and supply agreement for China for Bio-Thera’s B

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, today announced that management will present at the LD 500 virtual investor conference, hosted by LD Micro and taking place virtually September 1 – 4, 2020.

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the underwriters of its previously announced public offering of common stock have fully exercised their option to purchase an additional 500,000 shares at the public offering price of $3.60 per share. After giving effect to the full exercise of the over-allotment option, the to

Ligand Announces Amgen’s KYPROLIS ® Approved by FDA as Combination Regimen with DARZALEX ® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma KYPROLIS is an Amgen product that utilizes Captisol ® in its formulation Approval based on the CANDOR and EQUULEUS Studies SAN DIEGO--( BUSINESS WIRE )-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Capti